The International Society of BioProcess Technology (ISBioTech) formed in 2010 to help the industry share data and methods for process development and the production of biologics.
Known for our expertise in organizing conferences within our targeted network, we strive to highlight applications that are the most challenging while providing real-life experiences from support labs, process development suites, and production facilities. The format of our meetings combines exceptional quality presentations and exhibits with unforgettable networking opportunities to help foster and build relationships and collaborations.
Our Viral Vectors program has received the most attention since our founding, followed by Baculovirus Expression Technology and Cellular Therapies. These three programs run concurrently during our annual Spring Meeting.
Our content has evolved continuously over the past decade as new technologies emerge. In response to a growing demand for mRNA and DNA-based vaccines and biologics, we launched our virtual Nucleic Acids meeting in January 2021. We look forward to a face-to-face Nucleic Acids in 2023, as well as our equally timely Waterside Antibody Conference.
In addition, we've periodically covered Critical Capabilities for Biologic Production that are otherwise overlooked such as Cell Banking and Characterization, Contaminant Control (our biosafety meeting), and Raw Materials Science & Control. These programs are currently in hiatus. Email us if you'd like to contribute to relaunching these programs in 2024 or beyond!
As a result of the SARS-CoV-2 pandemic, we converted our content to a virtual platform that provided the same quality as our live meetings, but unfortunately, without the in-person interaction that everyone so dearly values. We were thrilled to reestablish live, face-to-face interaction — with limited attendance — in 2022, having adopted an inclusive, hybrid format that allows for both in-person and virtual attendance.
ISBioTech has played a major role in the production of viral reference materials that can be used to qualify, or validate, internal reference materials and assays. Such reference materials can be extremely valuable to the organizations using them, and can provide regulators with the ability to more readily compare viral product submissions.
Adenovirus serotype 5 (Ad5) was produced in 2001 when all viral vector development was halted due to a lack of control on patient dosing. Today, this material is still used worldwide, and remains stable and sterile as determined by testing that is done every two years. Today, ISBioTech is helping to develop a Lentiviral Vector Reference Material, which is pending production.
All of the data for these materials is available on our website.
ISBioTech’s companion publication, the BioProcessing Journal (BPJ), was established in 2002 to provide in-depth coverage of the type of content presented at our meetings. All manuscripts are peer reviewed by an exceptional Editorial Advisory Board (EAB), and are now published via an Open Access model. Authors are free to post their work wherever they please, in addition to what the journal makes available via its website, and these articles are frequently referenced in other papers published throughout the industry.
|Benefits of Joining ISBioTech|
While membership is not required to attend our meetings, we encourage dedicated biotech professionals to join our member base. Your annual support helps us produce top quality meeting content and published materials.
As a member, you'll receive a discounted rate for our meetings, as well as a discounted Open Access rate and preferential status when submitting manuscripts for publication in the BioProcessing Journal. In addition, members will receive communications on the latest developments in reference materials and standards.
|ISBioTech Annual Membership:|